CMS finalizes prior authorization timelines that exclude drugs

The Centers for Medicare & Medicaid Services published a final rule on February 8, 2024, setting new deadlines for how fast certain health plans must decide prior authorization requests ^[1]. Starting January 1, 2026, affected Medicare Advantage plans, Medicaid managed care plans, state Medicaid agencies, CHIP agencies and managed care entities, and issuers of qualified health plans on the federally-facilitated Exchanges must decide standard requests within 7 calendar days and expedited requests within 72 hours ^[1]. Plans must also give specific reasons when they deny a request ^[1].

The rule, known as CMS-0057-F, became effective April 8, 2024, though most compliance dates are staggered through 2026 and 2027 ^[1]. One section of the rule specifically addresses which services are covered. According to the document's table of contents, the rule includes an "Exclusion of Drugs" provision ^[1]. That means the new 7-day and 72-hour clocks apply to items and services, but not to drug coverage decisions ^[1].

This distinction matters directly for people prescribed GLP-1 medications such as semaglutide (sold as Ozempic, Wegovy, or Rybelsus) or tirzepatide (sold as Mounjaro or Zepbound). Because these are drugs, not medical services or items, a prior authorization request for one of them would not be bound by the new federal timelines once the rule takes effect in 2026 ^[1]. The rule's scope covers Medicare Advantage organizations, Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, and Exchange qualified health plan issuers ^[1].

The source document does not specify how long a drug-related prior authorization can currently take under these plans, or whether any other federal or state rule sets a deadline for drug prior authorizations. That information is not yet known from the material provided.

Why it matters for patients

Many patients seeking coverage for GLP-1 drugs already go through prior authorization, a process where a health plan reviews a prescription before agreeing to pay for it. The new CMS rule was designed to speed up and add transparency to prior authorization generally, requiring plans to act within 7 days for standard requests and 72 hours for urgent ones, and to explain any denial ^[1]. But because the rule excludes drugs, a patient waiting on approval for a GLP-1 prescription cannot count on those same speed guarantees under this particular federal rule ^[1].

This gap means the timeline for a drug-specific prior authorization could remain whatever it is today under each plan's own policies, since the source material does not describe any drug-specific deadline taking its place. For people managing conditions like type 2 diabetes or obesity who rely on timely medication access, this distinction between "items and services" and "drugs" in federal regulation could shape how quickly they learn whether their health plan will cover a GLP-1 prescription, even after the broader rule takes full effect ^[1].

What happens next

The rule was effective April 8, 2024 ^[1]. The 7-calendar-day standard and 72-hour expedited decision deadlines, along with the requirement to provide specific denial reasons, begin January 1, 2026, for the affected payer types ^[1]. The source document does not detail any separate rulemaking or timeline addressing prior authorization deadlines specifically for prescription drugs, including GLP-1 medications. Whether CMS or other regulators will address that gap is not yet known from the material available.